ValuEngine upgraded shares of Kura Oncology (NASDAQ:KURA) from a hold rating to a buy rating in a research note released on Wednesday morning.
KURA has been the topic of several other reports. Zacks Investment Research upgraded Kura Oncology from a sell rating to a buy rating and set a $18.00 price target on the stock in a research note on Tuesday, October 16th. Cann started coverage on Kura Oncology in a research note on Monday, November 5th. They set a buy rating and a $35.00 price target on the stock. BidaskClub upgraded Kura Oncology from a hold rating to a buy rating in a research note on Thursday, July 12th. HC Wainwright set a $31.00 price target on Kura Oncology and gave the company a buy rating in a research note on Thursday, November 1st. Finally, Cowen restated a buy rating on shares of Kura Oncology in a research note on Monday, October 22nd. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of Buy and an average target price of $27.29.
KURA traded up $0.08 on Wednesday, hitting $11.99. 257,032 shares of the stock traded hands, compared to its average volume of 398,285. Kura Oncology has a 52 week low of $10.20 and a 52 week high of $24.02. The company has a quick ratio of 10.22, a current ratio of 14.76 and a debt-to-equity ratio of 0.02. The firm has a market capitalization of $459.87 million, a price-to-earnings ratio of -7.89 and a beta of 4.39.
Kura Oncology (NASDAQ:KURA) last issued its quarterly earnings results on Monday, November 5th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.41) by $0.01. Equities research analysts expect that Kura Oncology will post -1.73 EPS for the current year.
Several hedge funds have recently added to or reduced their stakes in KURA. Voya Investment Management LLC bought a new stake in shares of Kura Oncology in the 2nd quarter valued at approximately $187,000. Trexquant Investment LP bought a new stake in shares of Kura Oncology in the 3rd quarter valued at approximately $217,000. Los Angeles Capital Management & Equity Research Inc. bought a new stake in shares of Kura Oncology in the 2nd quarter valued at approximately $218,000. BB&T Securities LLC bought a new stake in shares of Kura Oncology in the 2nd quarter valued at approximately $291,000. Finally, Bank of America Corp DE grew its stake in shares of Kura Oncology by 327.1% in the 2nd quarter. Bank of America Corp DE now owns 17,729 shares of the company’s stock valued at $323,000 after purchasing an additional 13,578 shares during the period. Institutional investors own 77.28% of the company’s stock.
About Kura Oncology
Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancers. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia.
Featured Story: How is Preferred Stock Different from Common Stock?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.